- PHCCC
-
- $35.00 / 2mg
-
2026-01-27
- CAS:179068-02-1
- Min. Order:
- Purity: 99.31%
- Supply Ability: 10g
|
| Product Name: | PHCCC | | Synonyms: | 7,7a-Dihydro-7-(hydroxyimino)-N-phenylbenzo[b]cyclopropa[e]pyran-1a(1H)-carboxamide;Benzo[b]cyclopropa[e]pyran-1a(1H)-carboxamide, 7,7a-dihydro-7-(hydroxyimino)-N-phenyl-;PHCCC >=97% (HPLC);Cyclopropa[b][1]benzopyran-1a(1H)-carboxamide,7,7a-dihydro-7-(hydroxyimino)-N-phenyl-,(7Z)-;(7Z)-7-hydroxyimino-N-phenyl-1,7a-dihydrocyclopropa[b]chromene-1a-carboxamide;(-) PHCCC;7-(Hydroxyimino)-N-phenyl-7,7a-dihydrocyclopropa[b]chromene-1a(1H)-carboxamide;allosteric,disease,Metabotropic glutamate receptors,Inhibitor,PHCCC,neurons,neuroprotective,mGluR,Parkinson's,inhibit | | CAS: | 179068-02-1 | | MF: | C17H14N2O3 | | MW: | 294.3 | | EINECS: | | | Product Categories: | | | Mol File: | 179068-02-1.mol |  |
| | PHCCC Chemical Properties |
| storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | Soluble in DMSO | | form | Powder | | color | White to off-white | | InChI | 1S/C17H14N2O3/c20-16(18-11-6-2-1-3-7-11)17-10-13(17)15(19-21)12-8-4-5-9-14(12)22-17/h1-9,13,21H,10H2,(H,18,20)/b19-15+ | | InChIKey | FPXPIEZPAXSELW-XDJHFCHBSA-N | | SMILES | O=C(NC1=CC=CC=C1)C2(C/3C2)OC4=C(C=CC=C4)C3=N/O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | PHCCC Usage And Synthesis |
| Uses | PHCCC is a Group I mGluR antagonist with an IC50 of 3 μM. PHCCC is a selective positive modulator of mGlu4 receptor. Antiparkinsonian effect[1][2]. | | Definition | ChEBI: 7-hydroxyimino-N-phenyl-1,7a-dihydrocyclopropa[b][1]benzopyran-1a-carboxamide is a 1-benzopyran. | | Biological Activity | PHCCC is a positive allosteric modulator (PAM) at the mGluR4 subtype th at exhibits anxiolytic and anti-Parkinsonian effects in animal models. PHCCC is a potent group I metabotropic glutamate receptor antagonist. | | in vivo | PHCCC (75 nmol/2.5 μl; intracerebroventricular) produces an antiparkinsonian effect in a dopamine depletion akinesia model[2]. | | IC 50 | Group I mGluR receptors: 3 μM (IC50) | | storage | Store at RT | | References | [1] Récasens M, et al. Metabotropic glutamate receptors as drug targets. Curr Drug Targets. 2007;8(5):651-681. DOI:10.2174/138945007780618544
[2] Marino MJ et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13668-73. DOI:10.1073/pnas.1835724100 |
| | PHCCC Preparation Products And Raw materials |
|